



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **Meade et al.**

Art Unit No.: **1632**

Application No.: **10/081,400**

Examiner: **Joseph T. Woitach**

Filed: **February 20, 2002**

For: **ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION**

Attorney Docket Number: **GTC-6D**

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY/AMENDMENT AFTER FINAL

Dear Sir,

This reply is being filed in response to the Office Action mailed September 19, 2005 in connection with the above-identified patent application. Upon review of the specification and claims it was found that the nucleotide sequence disclosure contained in this application did not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821-1.825. No new matter is entered. As such, Applicant respectfully requests that the above-identified application be amended as follows:


Amendments to the Specification are reflected on page 2 of this paper.

Amendments to the Claims begin on page 4 of this paper.

Remarks begin on page 7 of this paper.

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited on 9/29/05 with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Dawn C. Greenaway